Bevacizumab (Injection For Infusion)


Indications and Reactions:

Role Indications Reactions
Secondary
Non-small Cell Lung Cancer 47.9%
Oesophageal Carcinoma 11.7%
Pancreatic Carcinoma Metastatic 9.6%
Pancreatic Carcinoma 4.8%
Neoplasm Malignant 3.9%
Ovarian Cancer 2.8%
Gastrointestinal Carcinoma 2.5%
Colorectal Cancer Metastatic 2.3%
Metastatic Neoplasm 2.1%
Lung Neoplasm Malignant 1.8%
Bile Duct Cancer 1.4%
Lung Adenocarcinoma 1.4%
Hepatic Neoplasm Malignant 1.2%
Anaplastic Astrocytoma 1.1%
Lung Cancer Metastatic 1.1%
Squamous Cell Carcinoma 1.1%
Hepatic Neoplasm Malignant Non-resectable 1.0%
Colorectal Cancer 0.8%
Glioblastoma 0.8%
Glioblastoma Multiforme 0.8%
Pulmonary Embolism 18.7%
Vomiting 10.3%
White Blood Cell Count Decreased 9.7%
Weight Decreased 6.5%
Thrombocytopenia 5.8%
Oesophagitis 4.5%
Pain 4.5%
Small Intestinal Obstruction 4.5%
Tricuspid Valve Incompetence 3.9%
Neutropenia 3.2%
Pneumonia 3.2%
Sepsis 3.2%
Sudden Death 3.2%
Urinary Tract Infection 3.2%
Haemoglobin Decreased 2.6%
Haemoptysis 2.6%
Non-small Cell Lung Cancer 2.6%
Performance Status Decreased 2.6%
Rectal Haemorrhage 2.6%
Staphylococcal Infection 2.6%

Drug Data